MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/hae.14664

Медицинская библиотека · Haemophilia : the official journal of the World Federation of Hemophilia · 2022

Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single-institution experience.

Chen Evan C, Gibson William, Temoczko Paula, Connell Nathan T, Handin Robert, Parnes Aric D

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Acquired haemophilia A (AHA) is a rare and potentially life-threatening bleeding disorder arising from autoantibodies that inhibit coagulation factor VIII (FVIII). Treatment entails achieving haemostasis with bypassing agents or factor replacement, and eradication of the inhibitor with immunosuppressive therapy (IST). Due to the rarity of AHA, there are few prospective data to guide management.

METHODS

We present a retrospective report of 11 AHA patients treated with emicizumab, a FVIII-mimetic bispecific antibody, administered at 3 mg/kg weekly for 4 weeks in conjunction with rituximab-based immunosuppressive therapy. The chromogenic FVIII inhibitor assay was used to assess for inhibitor eradication.

RESULTS

The median follow-up was 13.9 months. The median number of days of additional haemostatic therapy or red blood cell transfusions after initiating emicizumab was 2 (range 0-15). The median was 0 days (range 0-8) for patients who did not require vascular embolization to achieve haemostasis. Eight patients achieved a complete remission (defined as recovery of FVIII activity to > 50% with a negative inhibitor test in the absence of haemostatic and IST); two patients achieved a partial remission (FVIII activity > 50% but with detectable inhibitor); one patient experienced refractory disease. One patient experienced rebleeding and two patients experienced inhibitor recurrence. No thrombotic, thrombotic microangiopathic or infectious complications occurred.

CONCLUSION

Our observations suggest emicizumab can facilitate haemostasis for AHA patients and be combined with safer, lower-intensity immunosuppressive therapies to achieve remission.

Для цитирования: Chen Evan C, Gibson William, Temoczko Paula, Connell Nathan T, Handin Robert, Parnes Aric D. Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single-institution experience.. Haemophilia : the official journal of the World Federation of Hemophilia. 2022. DOI: 10.1111/hae.14664.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.